SILQ has raised $20.0M in total across 2 funding rounds.
SILQ's investors include Amplify Partners, Flybridge Capital Partners, foobar.vc, Forum Ventures, Founders' Co-op, Founders Fund, F Prime Capital, Greycroft, Insight Partners, Partners Resolute, Redpoint Ventures, Saga.
Silq Technologies is a technology company specializing in advanced biomaterials for surface transformation, developing patented, drug-free surface treatments that resist organic material adhesion to enhance product effectiveness, efficiency, and safety.[2][3][4] It serves medical device manufacturers, implant producers, and industrial sectors like microfluidics, biopharma tubing, lithium-ion batteries, and water treatment, solving problems such as infections, biofouling, friction, and inefficiency—exemplified by its FDA-cleared Silq ClearTract® Foley Catheters, now available direct-to-patient.[2] A separate entity, Silq (onesilq.com), operates as a digital freight forwarder providing factory visibility, real-time tracking, and supply chain tools for apparel and consumer brands like Barry’s and Mizzen+Main, accelerating speed-to-market and quality.[1][5] Growth momentum includes commercial product launches for Silq Technologies and investments like F-Prime Capital's 2022 backing for the supply chain Silq.[1][2]
Silq Technologies emerged from cutting-edge research at the University of California Los Angeles, leveraging advanced material science to create scalable, environmentally friendly surface modifications for silicones and plastics used in medical and industrial applications.[2] Key leaders include Verne Sharma (CEO and Board Member, MBA), Jack Kavanaugh (MD, MBA, Chairman and Chief Scientific Advisor), and a Chief Technology Officer, driving its focus from research to FDA-cleared products like ClearTract® catheters.[3] The supply chain Silq, based in San Francisco, gained early traction post-2022 F-Prime Capital investment, building on on-site factory experts and proprietary tech to serve DTC brands, with pivotal customers like Pinpoint Merchandising.[1][5]
Silq Technologies rides the biomaterials and medtech innovation wave, addressing rising demands for infection-resistant implants amid aging populations and antimicrobial resistance trends, with its eco-friendly platform aligning with sustainability pushes in healthcare and industry.[2][3] Timing benefits from post-pandemic supply chain scrutiny and FDA efficiencies for surface tech. The supply chain Silq taps global logistics digitization, countering disruptions via AI visibility amid nearshoring and e-commerce growth in consumer goods.[1][5] Together, they enhance ecosystem resilience—Silq Tech via life-improving devices, supply chain Silq via predictable manufacturing—amplifying tech's role in health and commerce efficiency.
Silq Technologies eyes expansion of its platform into more devices, biopharma, and batteries, fueled by clinical data and partnerships, while navigating regulatory scaling.[2][3] The supply chain Silq will likely deepen AI analytics and global hubs amid e-commerce booms.[1][5] Trends like AI-medtech fusion and resilient supply chains position both for outsized impact, evolving from niche innovators to ecosystem shapers—echoing their missions to transform surfaces and shipping with radical visibility.
SILQ has raised $20.0M across 2 funding rounds. Most recently, it raised $18.0M Series A in March 2022.
